RecruitingNCT05820672
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)
Sponsor
Ascendis Pharma Endocrinology Division A/S
Enrollment
900 participants
Start Date
Mar 20, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Eligibility
Min Age: 1 YearMax Age: 18 Years
Inclusion Criteria3
- Patients who are on treatment with SKYTROFA (lonapegsomatropin)
- Patients being clinically managed in USA
- Patients with an appropriate written informed consent/assent as applicable for the age of the patient
Exclusion Criteria1
- Patients participating in any interventional clinical study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNo intervention
No intervention
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05820672
Related Trials
Effects of GH and Lirglutide on AgRP
NCT056812991 location
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
NCT0577552327 locations
Chromosome 18 Clinical Research Center
NCT002272532 locations
Evaluation of the Propensity of Patients Under rhGH to Envision a Modification of Their Treatment Regimen Toward LAGH
NCT065428091 location
Use of miRNAs in Growth Hormone Deficiency (GHD)
NCT064559561 location